Sort
48,018 grants matching “immunotherapy”
Formulation to Generate Tolerance Towards Type 1 Diabetes
$381,816Kristy M Ainslie · Univ Of North Carolina Chapel Hill · R01 · FY2022 · DK
Project 1: Overcoming Immune Exclusion in Microsatellite Stable Colorectal Cancer
$381,800Robert J Coffey · Vanderbilt University Medical Center · P50 · FY2025 · CA
Mismatch Repair and Carcinogenesis
$381,773Richard Fishel · Ohio State University · R01 · FY2025 · CA
Skin Defense by Dermal Adipocytes
$381,700Richard L Gallo · University Of California, San Diego · R01 · FY2019 · AR
Optimal Pairing of Chemotherapy with Immunotherapy for Pancreatic Cancer
$381,692Peter A Cohen · Mayo Clinic Rochester · P50 · FY2015 · CA
Immune response to Pneumocystis in simian model of AIDS
$381,682Karen A Norris · University Of Pittsburgh At Pittsburgh · R01 · FY2009 · HL
Novel Nanotechnologies and Molecular Imaging Approaches for Cancer Immunotherapy
$381,654Caius Gabriel Radu · California Institute Of Technology · U54 · FY2010 · CA
Stress Pathways in Tumors Drive Global MDSC Activity and Survival through Chop
$381,646Paulo Cesar Rodriguez · H. Lee Moffitt Cancer Ctr & Res Inst · R01 · FY2019 · CA
Augmenting T cell trafficking and functionality through novel combinations of epigenetic agents and PD-1 blockade
$381,646Amer Aziz Beg · H. Lee Moffitt Cancer Ctr & Res Inst · R01 · FY2019 · CA
Immunogenicity & efficacy of chimeric flu virus expressing Ab42 B cell epitope
$381,631Michael G Agadjanyan · Institute For Molecular Medicine · R01 · FY2009 · NS
Immunogenicity & efficacy of chimeric flu virus expressing Ab42 B cell epitope
$381,631Michael G Agadjanyan · Institute For Molecular Medicine · R01 · FY2008 · NS
Quantitatively modeling immune responses to cancer
$381,625Matthew Spitzer · University Of California, San Francisco · DP5 · FY2016 · OD
Adoptive Immunotherapy of Cancer with IL-12 Secreting Tumor-Targeted T cells
$381,617Renier Joseph Brentjens · Sloan-Kettering Inst Can Research · R01 · FY2011 · CA
Adoptive Immunotherapy of Cancer with IL-12 Secreting Tumor-Targeted T cells
$381,617Renier Joseph Brentjens · Sloan-Kettering Inst Can Research · R01 · FY2012 · CA
Formulation to Generate Tolerance Towards Type 1 Diabetes
$381,608Kristy M Ainslie · Univ Of North Carolina Chapel Hill · R01 · FY2023 · DK
Imaging tumor associated macrophage (TAM) function
$381,606Ralph Weissleder · Massachusetts General Hospital · R01 · FY2017 · CA
Project 1: Evaluating the synergy of LAG3 and PD-1 in melanoma patients
$381,600Dario Aa Vignali · University Of Pittsburgh At Pittsburgh · P50 · FY2024 · CA
Project 3: Localized microneedle-directed combination immunotherapy for cSCC
$381,600Louis D Falo · University Of Pittsburgh At Pittsburgh · P50 · FY2024 · CA
Multi-color Mapping of Cancer Molecular Signatures and Tumor microenvironment
$381,589Jenny J Yang · Georgia State University · R33 · FY2021 · CA
EASTERN COOPERATIVE ONCOLOGY GROUP
$381,557Tufts Medical Center · U10 · FY2002 · CA
Design and Synthesis of O-GalNAc and O-Man Peptides for Biomedical Studies
$381,515Ernest G Nolen · Colgate University · R15 · FY2017 · GM
The role of CEACAM1 in oncogenic B-cell receptor signaling and immunotherapy in mantle cell lymphoma
$381,482Vu Nguyen Ngo · Beckman Research Institute/City Of Hope · R01 · FY2024 · CA
Regulatory mechanisms of miR-19b, a novel mediator of T cell autoimmunity
$381,478Qijing Li · Duke University · R01 · FY2015 · AI
Transcriptional mechanisms and melanoma
$381,460Leonard I Zon · Massachusetts General Hospital · P01 · FY2019 · CA
A Novel Symbiotic Approach for Ovarian Cancer
$381,419Jogender Tushir-Singh · University Of California At Davis · R01 · FY2021 · CA